Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) insider John Militello sold 833 shares of the company's stock in a transaction on Monday, April 22nd. The stock was sold at an average price of $22.87, for a total transaction of $19,050.71. Following the completion of the transaction, the insider now directly owns 54,406 shares in the company, valued at approximately $1,244,265.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
John Militello also recently made the following trade(s):
- On Thursday, March 21st, John Militello sold 2,490 shares of Rocket Pharmaceuticals stock. The shares were sold at an average price of $28.10, for a total value of $69,969.00.
- On Thursday, February 29th, John Militello sold 10,000 shares of Rocket Pharmaceuticals stock. The shares were sold at an average price of $29.84, for a total value of $298,400.00.
Rocket Pharmaceuticals Trading Down 0.2 %
NASDAQ RCKT opened at $23.63 on Thursday. Rocket Pharmaceuticals, Inc. has a 1-year low of $14.89 and a 1-year high of $32.53. The stock has a 50-day moving average of $26.97 and a 200-day moving average of $25.44. The company has a debt-to-equity ratio of 0.04, a current ratio of 7.80 and a quick ratio of 7.80.
Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years
From Banyan Hill Publishing | Ad
If you think AI is big, then you have got to check out something I call Imperium…
By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)
Watch my video for all of the details
Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last announced its quarterly earnings results on Monday, February 26th. The biotechnology company reported ($0.64) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.14. During the same period in the previous year, the firm earned ($0.92) earnings per share. Research analysts expect that Rocket Pharmaceuticals, Inc. will post -2.94 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on RCKT. Needham & Company LLC reissued a "buy" rating and set a $53.00 price objective on shares of Rocket Pharmaceuticals in a report on Wednesday, April 10th. StockNews.com raised shares of Rocket Pharmaceuticals to a "sell" rating in a report on Friday, February 9th. The Goldman Sachs Group initiated coverage on shares of Rocket Pharmaceuticals in a report on Tuesday, April 2nd. They set a "neutral" rating and a $39.00 price objective for the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $65.00 target price on shares of Rocket Pharmaceuticals in a research note on Tuesday, February 27th. Finally, UBS Group dropped their price target on Rocket Pharmaceuticals from $56.00 to $54.00 and set a "buy" rating for the company in a research note on Friday, March 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $52.13.
View Our Latest Research Report on RCKT
Institutional Investors Weigh In On Rocket Pharmaceuticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RCKT. Hennion & Walsh Asset Management Inc. raised its stake in shares of Rocket Pharmaceuticals by 19.6% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 231,287 shares of the biotechnology company's stock valued at $6,231,000 after acquiring an additional 37,937 shares during the last quarter. Harbour Capital Advisors LLC increased its holdings in Rocket Pharmaceuticals by 115.3% during the 1st quarter. Harbour Capital Advisors LLC now owns 21,155 shares of the biotechnology company's stock valued at $544,000 after purchasing an additional 11,330 shares during the period. Vanguard Group Inc. raised its position in Rocket Pharmaceuticals by 18.3% during the 4th quarter. Vanguard Group Inc. now owns 5,447,565 shares of the biotechnology company's stock valued at $163,264,000 after purchasing an additional 843,552 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Rocket Pharmaceuticals by 2.2% in the 4th quarter. Wellington Management Group LLP now owns 8,197,546 shares of the biotechnology company's stock worth $245,680,000 after buying an additional 174,716 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in Rocket Pharmaceuticals by 12.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 594,665 shares of the biotechnology company's stock worth $17,822,000 after buying an additional 64,946 shares during the period. 98.39% of the stock is currently owned by institutional investors.
Rocket Pharmaceuticals Company Profile
(
Get Free Report)
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
